NuVasive to acquire Osiris unit

05/8/2008 | Houston Chronicle (tiered subscription model)

NuVasive will purchase Osteocol, a subsidiary of Osiris Therapeutics, in a deal that allows it to gain access to the unit's developing stem cell technology and expand into the biotech market. The acquisition, which will close in the third quarter, includes $35 million in cash and future milestone payments to Osiris worth up to $50 million.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID